NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Peptide testing

Ordered GHK-Cu from Shanxi Qianyecao Biotech QYC? Mail in a sample (US only) and let us test it.

Test my supply
+12 more ↓
89%
Finnrick rating
#19 of 156 GHK-Cu vendors
12 of 13 classifiable tests passed
natural 92% · customers 4.7★ (4)
methodology · Purity focus
Finnrick analysis · GHK-Cu

Shanxi Qianyecao Biotech QYC's GHK-Cu has a documentation caveat: nearly all tests lacked batch IDs, and one early vial missed purity at 91.46%. Later results show steady recovery with passing identity, high purity, and in-range fill.

methodology →
vendor intelligence report
Vendor Intelligence Report: Shanxi Qianyecao Biotech QYC

Registry filings, WHOIS records and public-channel checks trace QYC from a cancelled PRC entity to a late-2026 verification collapse. The report also follows Revivix COAs, payment-rail changes and the unresolved control behind Amy-QYC.

35 pages7 risk factors assessed12 Nov 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cuselected
$0.08
89%
13
2
Tirzepatide
$0.47
81%
22
3
Retatrutide
$1.20
73%
53
4
PT-141
$1.80
72%
3
5
Ipamorelin
$1.00
60%
5
6
Tesamorelin
$1.90
57%
12
7
Sermorelin
$2.00
48%
3
8
BPC-157
$1.29
46%
8
9
TB-500
$3.00
41%
4
10
Cagrilintide
$2.40
39%
5
11
NAD+
-
22%
4
12
CJC-1295
$2.00
-
0
13
Epithalon
$0.30
-
0
15
HGH
-
-
0
16
KLOW
-
-
0
17
KPV
-
-
0
18
Semaglutide
$2.00
-
0
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%25 Sep 2025: 81%25 Nov 2025: 83%25 Nov 2025: 83%26 Jan 2026: 86%2 Feb 2026: 87%2 Feb 2026: 87%4 Feb 2026: 87%18 Feb 2026: 88%22 Feb 2026: 89%2 Mar 2026: 90%28 Apr 2026: 91%28 Apr 2026: 91%9 Aug 2026: 91%15 Nov 2026: current 89%81%88%89%Sep 25Nov 26
Showing GHK-Cu tests only
Peptide testing

Ordered GHK-Cu from Shanxi Qianyecao Biotech QYC? Mail in a sample (US only) and let us test it.

Test my supply
Shanxi Qianyecao Biotech QYC GHK-Cu test history
COA-backed lab tests
1-10 of 13

About Shanxi Qianyecao Biotech QYC test results from Finnrick

Shanxi Qianyecao Biotech QYC is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 11 peptides and 132 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Shanxi Qianyecao Biotech QYC peptides in this dataset are BPC-157 (8 tests), Cagrilintide (5 tests) and GHK-Cu (13 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 132 recent tests. It also includes 1 correction related to this vendor.

Corrections
2026-08-17
Finnrick data entry
The requester submitted the NAD+ sample with a declared potency of 50 mg. The correct potency is 500 mg. The recorded data has been corrected to reflect the accurate potency of 500 mg.
Peptide testing

Ordered GHK-Cu from Shanxi Qianyecao Biotech QYC? Mail in a sample (US only) and let us test it.

Test my supply